Assembly Biosciences Abstracts Selected for Presentation at the Upcoming AASLD The Liver Meeting®
02 November 2021 - 01:32AM
Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage
biotechnology company developing innovative therapeutics targeting
hepatitis B virus (HBV), today announced that clinical and
preclinical data from its HBV core inhibitor program will be
featured in one oral and two poster presentations, including one
late breaking, during the American Association for the Study of
Liver Diseases (AASLD) The Liver Meeting
®. The
presentations include updates from the clinical studies of
vebicorvir (VBR) and ABI-H3733, as well as the newly selected
preclinical core inhibitor candidate, ABI-4334. AASLD will be
hosted virtually November 12-15, 2021.
“The Liver Meeting offers a valuable opportunity to further
advance our understanding of HBV and liver disease, while gaining
access to the latest cutting-edge research from the world’s leading
liver disease experts,” said John McHutchison, AO, MD, chief
executive officer and president of Assembly Bio. “We continue to
believe that therapeutics targeting the HBV core protein will offer
a long-awaited breakthrough for individuals living with HBV, and we
are excited to share what we’ve learned through our latest
findings. This year, we’re also looking forward to more formally
introducing the AASLD community to ABI-4334, a new compound with a
potential best-in-class preclinical profile including single digit
nanomolar potency against the formation of cccDNA.”
- Oral Presentation
#96: HBV pgRNA and DNA both
rebound immediately following discontinuation of the core inhibitor
vebicorvir despite continued NrtI treatment in patients with HBeAg
positive chronic hepatitis B virus infection: Findings from a Phase
2 open label studyPresenter: Man-Fung Yuen, MD,
PhD, DSc, Queen Mary Hospital, University of Hong
KongSession: Parallel 13:
Novel HBV Therapies and Approaches Date and
Time: Sunday, November 14, 2021, 10:00 AM – 11:30 AM
ET
- Poster Presentation
#842: Safety and pharmacokinetics
of ABI-H3733, a novel 2nd-generation HBV core inhibitor: Results
from a Phase 1a study in healthy
volunteersPresenter: Edward Gane, MBChB, MD
FRACP, MNZM, New Zealand Liver Transplant Unit, Auckland City
Hospital, New ZealandSession: Hepatitis B:
Therapeutics: New Agents
- Late-breaking Poster
LP4: Preclinical characterization
of ABI-4334, a novel, highly potent core inhibitor for the
treatment of chronic hepatitis B virus
infectionPresenter: Kathryn M. Kitrinos, PhD, Vice
President, Clinical Virology, Assembly
BiosciencesSession: Late-breaking Abstract
Posters
AASLD Presentations and
PostersPresentations and posters are expected to be made
available to conference registrants through the online AASLD portal
at 8:00 am ET Friday, November 12, and will be available
subsequently on the “Events & Presentations” page in the
“Investors” section of Assembly's website
at www.assemblybio.com.
About Assembly BiosciencesAssembly Bio is
a clinical-stage biotechnology company committed to bringing finite
and curative therapies to the 270 million people living with
hepatitis B virus (HBV) worldwide. A pioneer in the development of
a new class of potent, oral core inhibitor drug candidates,
Assembly Bio’s approach aims to break the complex viral replication
cycle of HBV to free patients from a lifetime of therapy. Assembly
Bio’s strategy toward cure includes a leading portfolio of more
potent, next-generation core inhibitors, proof-of-concept
combination studies and a research program focused on the discovery
of novel HBV targets. For more information, visit
assemblybio.com.
Forward-Looking StatementsThe information in
this press release contains forward-looking statements that are
subject to certain risks and uncertainties that could cause actual
results to materially differ. These risks and uncertainties
include: Assembly Bio’s ability to initiate and complete clinical
studies involving its HBV therapeutic product candidates, including
studies contemplated by Assembly Bio’s clinical collaboration
agreements, in the currently anticipated timeframes; safety and
efficacy data from clinical studies may not warrant further
development of Assembly Bio’s product candidates; clinical and
nonclinical data presented at conferences may not differentiate
Assembly Bio’s product candidates from other companies’ candidates;
results of nonclinical studies may not be representative of disease
behavior in a clinical setting and may not be predictive of the
outcomes of clinical studies; continued development and
commercialization of Assembly Bio’s HBV product candidates, if
successful, in the China territory will be dependent on, and
subject to, Assembly Bio’s collaboration agreement governing its
activity in the China territory; Assembly Bio’s ability to maintain
financial resources necessary to continue its clinical studies and
fund business operations; any impact that the COVID-19 pandemic may
have on Assembly Bio’s business and operations, including
initiation and continuation of its clinical studies or timing of
discussions with regulatory authorities; and other risks identified
from time to time in Assembly Bio’s reports filed with the U.S.
Securities and Exchange Commission (the SEC). You are urged to
consider statements that include the words may, will, would, could,
should, might, believes, hopes, estimates, projects, potential,
expects, plans, anticipates, intends, continues, forecast,
designed, goal or the negative of those words or other comparable
words to be uncertain and forward-looking. Assembly Bio intends
such forward-looking statements to be covered by the safe harbor
provisions contained in Section 27A of the Securities Act of 1933,
as amended, and Section 21E of the Securities Exchange Act of 1934,
as amended. More information about Assembly Bio’s risks and
uncertainties are more fully detailed under the heading “Risk
Factors” in Assembly Bio’s filings with the SEC, including its most
recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q
and Current Reports on Form 8-K. Except as required by law,
Assembly Bio assumes no obligation to update publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise.
ContactsInvestor and Corporate:Lauren
GlaserSenior Vice President, Investor Relations and Corporate
Affairs(415) 521-3828lglaser@assemblybio.com
Media:Sam Brown Inc. Audra Friis (917)
519-9577 ASMBMedia@sambrown.com
Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart
From Feb 2024 to Mar 2024
Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart
From Mar 2023 to Mar 2024